Novo Nordisk’s Wegovy and copyright, the two driven by semaglutide, have revolutionized being overweight cure by means of unprecedented weight loss outcomes.In October 2024, Novo Nordisk published a research on scientific journal Mother nature about a novel glucose-sensitive insulin NNC2215 that may minimize the chance of hypoglycemia in animal v